1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
2
|
Lacroix M, Abi-Said D, Fourney DR,
Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch
SJ, Holland E, et al: A multivariate analysis of 416 patients with
glioblastoma multiforme: Prognosis, extent of resection, and
survival. J Neurosurg. 95:190–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
3
|
Kim B, Myung JK, Seo JH, Park CK, Paek SH,
Kim DG, Jung HW and Park SH: The clinicopathologic values of the
molecules associated with the main pathogenesis of the
glioblastoma. J Neurol Sci. 294:112–118. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Ohgaki H and Kleihues P: Genetic
alterations and signaling pathways in the evolution of gliomas.
Cancer Sci. 100:2235–2241. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Deng C, Zhang P, Harper JW, Elledge SJ and
Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but
are defective in G1 checkpoint control. Cell. 82:675–684. 1995.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Slampa P: Gliomy-soucasná diagnostika a
lecba. Maxdorf. 97–102. 2013.(In Czech).
|
7
|
Takano S, Yoshii Y, Kondo S, Suzuki H,
Maruno T, Shirai S and Nose T: Concentration of vascular
endothelial growth factor in the serum and tumor tissue of brain
tumor patients. Cancer Res. 56:2185–2190. 1996.PubMed/NCBI
|
8
|
Shim JW, Koh YC, Ahn HK, Park YE, Hwang DY
and Chi JG: Expression of bFGF and VEGF in brain astrocytoma. J
Korean Med Sci. 11:149–157. 1996. View Article : Google Scholar : PubMed/NCBI
|
9
|
Oehring RD, Miletic M, Valter MM, Pietsch
T, Neumann J, Fimmers R and Schlegel U: Vascular endothelial growth
factor (VEGF) in astrocytic gliomas-a prognostic factor? J
Neurooncol. 45:117–125. 1999. View Article : Google Scholar : PubMed/NCBI
|
10
|
Toledo F and Wahl GM: MDM2 and MDM4: p53
regulators as target in anticancer therapy. Int J Biochem Cell
Biol. 39:1476–1482. 2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Oda K, Matsuoka Y, Funahashi A and Kitano
H: A comprehensive pathway map of epidermal growth factor receptor
signaling. Mol Syst Biol. 1:2005.00102005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Integrated genomic analysis identifies clinically relevant subtypes
of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell. 17:98–1101. 2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Knobbe CB, Reifenberger J and Reifenberger
G: Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and
BRAF in glioblastomas. Acta Neuropathol. 108:467–470. 2004.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Ruano Y, Ribalta T, de Lope AR,
Campos-Martín Y, Fiaño C, Pérez-Magán E, Hernández-Moneo JL,
Mollejo M and Meléndez B: Worse outcome in primary glioblastoma
multiforme with concurrent epidermal growth factor receptor and p53
alteration. Am J Clin Pathol. 131:257–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Sesen J, Dahan P, Scotland SJ, Saland E,
Dang VT, Lemarié A, Tyler BM, Brem H, Toulas C, Moyal
Cohen-Jonathan E, et al: Metformin inhibits growth of human
glioblastoma cells and enhances therapeutic response. PLoS One.
10:e01237212015. View Article : Google Scholar : PubMed/NCBI
|